Related Experiment Videos
Lipoprotein (a) regulates plasmin generation and inhibition
1Duke University Medical Center, Durham, NC 27710.
Chemistry and Physics of Lipids
|January 1, 1994
Summary
Lipoprotein (a) (Lp(a)) impacts blood clot breakdown (fibrinolysis) by inhibiting plasminogen activators and favoring plasmin inhibition. Its net effect on cardiovascular health depends on various protein concentrations in the body.
Area of Science:
- Biochemistry
- Cardiovascular Biology
- Molecular Medicine
Background:
- Lipoprotein (a) (Lp(a)) is linked to atherosclerosis.
- Recent studies explore Lp(a)'s role in fibrinolysis due to its structural similarity to plasminogen.
Purpose of the Study:
- To investigate the effects of Lp(a) on the fibrinolytic system.
- To elucidate the mechanisms by which Lp(a) influences plasmin generation and inhibition.
Main Methods:
- Surface-dependent inhibition of plasminogen activation by tissue-type plasminogen activator (t-PA) and urinary-type plasminogen activator (u-PA) when Lp(a) binds to fibrin, fibrinogen, heparin, or cells.
- Analysis of Lp(a)'s effect on plasmin inhibition by alpha 2-antiplasmin (alpha 2-AP).
- Investigation of Lp(a)'s influence on the interaction between t-PA, plasminogen activator inhibitor type 1 (PAI-1), fibrinogen, and heparin.
Main Results:
- Lp(a) inhibits plasminogen activation by t-PA and u-PA in a surface-dependent manner.
- Lp(a) promotes plasmin inhibition by alpha 2-AP by competing for fibrin binding.
- Lp(a) exhibits a profibrinolytic effect by blocking PAI-1 inhibition of t-PA under specific conditions.
Conclusions:
- Lp(a) significantly modulates key reactions in fibrinolysis, acting primarily in an antifibrinolytic manner.
- The overall in vivo impact of Lp(a) on fibrinolysis is determined by the concentrations of Lp(a), PAI-1, and t-PA.